https://media-us.eisai.com/index.php?s=20303 2023-02-15 weekly 0.5 https://media-us.eisai.com/pressreleases 2026-03-26 weekly 0.5 https://media-us.eisai.com/2026-03-26-EISAI-TO-BEGIN-ENROLLING-PHASE-2-STUDY-IN-PATIENTS-WITH-NARCOLEPSY 2026-03-26 weekly 0.5 https://media-us.eisai.com/2026-03-20-Results-from-Real-World,-Long-Term-Treatment-Persistence-with-LEQEMBI-R-lecanemab-irmb-in-the-United-States-Presented-at-AD-PD-TM-2026 2026-03-20 weekly 0.5 https://media-us.eisai.com/2026-03-10-Eisai-to-Present-the-Latest-Data-on-Long-Term,-Real-World-Treatment-with-Lecanemab-at-the-AD-PD-TM-2026-Annual-Meeting 2026-03-10 weekly 0.5 https://media-us.eisai.com/2026-02-26-Eisai-and-Advocacy-Leaders-Launch-Kompass,-a-Digital-Destination-to-Help-Patients-and-Caregivers-Navigate-the-Complexities-of-Kidney-Cancer 2026-02-26 weekly 0.5 https://media-us.eisai.com/2026-01-25-FDA-Accepts-LEQEMBI-R-IQLIKTM-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-under-Priority-Review 2026-01-25 weekly 0.5 https://media-us.eisai.com/2025-12-03-Eisai-Presents-New-Data-on-the-Continued-and-Expanding-Benefit-of-LEQEMBI-R-lecanemab-irmb-Maintenance-Treatment-in-Early-Alzheimers-Disease-at-the-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference-2025 2025-12-03 weekly 0.5 https://media-us.eisai.com/2025-12-02-New-Data-Presented-at-the-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference-2025-Confirms-Pharmacological-Effect-of-LEQEMBI-R-lecanemab-irmb-on-Neurotoxic-A-Protofibrils-in-CSF 2025-12-02 weekly 0.5 https://media-us.eisai.com/2025-12-01-Eisai-Presents-New-Data-on-Anti-Tau-Antibody-Etalanetug-E2814-at-CTAD-2025 2025-12-02 weekly 0.5 https://media-us.eisai.com/2025-11-25-Eisai-Completes-Rolling-Submission-to-U-S-FDA-for-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-Under-Fast-Track-Status 2025-11-25 weekly 0.5 https://media-us.eisai.com/2025-11-18-Eisai-to-Present-Data-on-Lecanemab-Continued-Treatment,-Subcutaneous-Initiation-Dosing,-and-Real-World-Experience-at-the-18th-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference 2025-11-18 weekly 0.5 https://media-us.eisai.com/2025-11-03-Eisai-Demonstrates-Commitment-to-Advanced-Endometrial-Cancer-Care-at-IGCS-2025 2025-12-04 weekly 0.5 https://media-us.eisai.com/2025-10-13-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Autoinjector-Named-to-TIMEs-Best-Inventions-of-2025 2025-10-14 weekly 0.5 https://media-us.eisai.com/2025-10-06-Eisai-and-Biogen-Announce-U-S-Availability-of-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease 2025-10-06 weekly 0.5 https://media-us.eisai.com/2025-10-02-Eisai-Highlights-Breadth-of-Oncology-Research-at-ESMO-2025,-Featuring-5-Year-Survival-Data-from-Study-309-KEYNOTE-775 2025-10-02 weekly 0.5 https://media-us.eisai.com/2025-09-16-Anti-MTBR-microtubule-binding-region-Tau-Antibody-Etalanetug-Granted-FDA-Fast-Track-Designation 2025-09-16 weekly 0.5 https://media-us.eisai.com/2025-09-08-Eisai-Presents-Clinical-Study-Results-of-Novel-Orexin-Receptor-Agonist-E2086-for-Narcolepsy-at-World-Sleep-2025 2025-09-10 weekly 0.5 https://media-us.eisai.com/2025-09-03-Eisai-to-Present-Latest-Data-on-Lemborexant-and-Novel-Orexin-Receptor-Agonist-E2086-at-The-World-Sleep-2025 2025-09-03 weekly 0.5 https://media-us.eisai.com/2025-09-02-Eisai-Initiated-Rolling-Supplemental-Biologics-License-Application-to-the-U-S-FDA-for-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-Under-Fast-Track-Status 2025-09-02 weekly 0.5 https://media-us.eisai.com/2025-08-29-FDA-Approves-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-for-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimers-Disease 2025-09-02 weekly 0.5 https://media-us.eisai.com/2025-07-30-Two-Year-Real-World-Study-of-LEQEMBI-R-in-the-United-States-Presented-at-Alzheimers-Association-International-Conference-AAIC-2025 2025-07-30 weekly 0.5 https://media-us.eisai.com/2025-07-30-New-Data-Presented-at-AAIC-Demonstrates-Investigational-LEQEMBI-R-lecanemab-irmb-360-mg-Subcutaneous-Maintenance-Dosing-Could-Offer-a-New-Option-for-Ongoing-Treatment-of-Early-Alzheimers-Disease 2025-07-30 weekly 0.5 https://media-us.eisai.com/2025-07-30-Early-Alzheimers-Patients-Continue-to-Benefit-from-Four-Years-of-LEQEMBI-R-lecanemab-irmb-Therapy-New-Clinical-Data-Presented-at-AAIC 2025-07-30 weekly 0.5 https://media-us.eisai.com/2025-07-21-EISAI-TO-PRESENT-FOUR-YEAR-EFFICACY-AND-SAFETY-DATA-ON-CONTINUOUS-TREATMENT-WITH-LECANEMAB-AT-THE-ALZHEIMERS-ASSOCIATION-INTERNATIONAL-CONFERENCE-2025 2025-07-22 weekly 0.5 https://media-us.eisai.com/2025-05-20-Eisai-Demonstrates-Commitment-to-Oncology-Innovation-at-ASCO-2025 2025-05-20 weekly 0.5 https://media-us.eisai.com/2025-03-25-EISAI-TO-PRESENT-LECANEMAB-REAL-WORLD-EXPERIENCE-DATA-AND-FINDINGS-FROM-NEUROLOGY-PORTFOLIO-AT-THE-AMERICAN-ACADEMY-OF-NEUROLOGY-AAN-ANNUAL-MEETING 2025-05-19 weekly 0.5 https://media-us.eisai.com/2025-02-28-The-Committee-for-Medicinal-Products-for-Human-Use-CHMP-Reaffirms-Positive-Opinion-for-Lecanemab-in-Early-Alzheimers-Disease 2025-05-09 weekly 0.5 https://media-us.eisai.com/2025-01-26-FDA-Approves-LEQEMBI-R-lecanemab-irmb-IV-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimers-Disease 2025-01-29 weekly 0.5 https://media-us.eisai.com/2025-01-13-FDA-Accepts-LEQEMBI-R-lecanemab-irmb-Biologics-License-Application-for-Subcutaneous-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimers-Disease 2025-01-16 weekly 0.5 https://media-us.eisai.com/2024-12-04-LEQEMBI-R-Lecanemab-Approved-for-the-Treatment-of-Early-Alzheimers-Disease-in-Mexico 2024-12-06 weekly 0.5 https://media-us.eisai.com/2024-11-27-LEQEMBI-R-Lecanemab-for-the-Treatment-of-Alzheimers-Disease-Launched-in-South-Korea 2024-12-05 weekly 0.5 https://media-us.eisai.com/2024-11-21-EISAI-SUPPORTS-SLEEP-RESEARCH-SOCIETY-FOUNDATION-EDUCATIONAL-WEBINAR-LESSONS-LEARNED-FROM-CENTRAL-DISORDERS-OF-HYPERSOMNOLENCE-AND-FUTURE-DIRECTIONS 2024-11-22 weekly 0.5 https://media-us.eisai.com/2024-11-14-Eisai-Receives-Positive-Opinion-from-the-CHMP-in-the-European-Union-for-Lecanemab-in-Early-Alzheimers-Disease 2024-11-19 weekly 0.5 https://media-us.eisai.com/2024-10-31-Eisai-Completes-Rolling-Submission-to-US-FDA-for-LEQEMBI-R-lecanemab-irmb-Biologics-License-Application-for-Subcutaneous-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimers-Disease-Under-the-Fast-Track-Status 2024-11-05 weekly 0.5 https://media-us.eisai.com/2024-10-30-EISAI-PRESENTS-LATEST-CLINICAL-FINDINGS-SUGGESTING-INHIBITION-OF-TAU-PROPAGATION-BY-ANTI-MTBR-TAU-ANTIBODY-E2814-AT-THE-17TH-CLINICAL-TRIALS-ON-ALZHEIMERS-DISEASE-CONFERENCE-CTAD 2024-11-05 weekly 0.5 https://media-us.eisai.com/2024-10-30-Eisai-Presents-Data-on-Benefits-of-Long-Term-Administration-of-Dual-Acting-Lecanemab-at-the-17th-Clinical-Trials-for-Alzheimers-Disease-CTAD-Conference 2024-11-05 weekly 0.5 https://media-us.eisai.com/2024-10-23-EISAI-TO-PRESENT-UPDATED-DUAL-ACTING-LECANEMAB-DATA,-RESEARCH-ON-BLOOD-BIOMARKERS-FOR-PREDICTING-PRESENCE-OF-AMYLOID-IN-THE-BRAIN-AND-NEW-FINDINGS-ON-THE-ANTI-MTBR-MICROTUBULE-BINDING-REGION-TAU-ANTIBODY-E2814-AT-THE-17TH-CLINICAL-TRIALS-FOR-AL 2024-10-25 weekly 0.5 https://media-us.eisai.com/2024-09-14-KEYTRUDA-R-pembrolizumab-Plus-LENVIMA-R-lenvatinib-in-Combination-With-Transarterial-Chemoembolization-TACE-Significantly-Improved-Progression-Free-Survival-Compared-to-TACE-Alone-in-Patients-With-Unresectable,-Non-Metastatic-Hepatocellular-Car 2024-09-19 weekly 0.5 https://media-us.eisai.com/2024-09-04-Eisai-Accelerates-Progress-in-Oncology-Research-with-New-Data-at-ESMO-Congress-2024,-Including-First-Interim-Analysis-Results-from-the-Phase-3-LEAP-012-Trial 2024-09-06 weekly 0.5 https://media-us.eisai.com/2024-08-22-Leqembi-R-lecanemab-Authorized-for-Early-Alzheimers-Disease-in-Great-Britain 2024-08-26 weekly 0.5 https://media-us.eisai.com/2024-08-13-LEQEMBI-R-Lecanemab-Approved-for-the-Treatment-of-Alzheimers-Disease-in-the-United-Arab-Emirates 2024-08-14 weekly 0.5 https://media-us.eisai.com/subscribe 2023-04-12 weekly 0.5